Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-12.42%
0%
-12.42%
6 Months
43.23%
0%
43.23%
1 Year
123.58%
0%
123.58%
2 Years
58.59%
0%
58.59%
3 Years
106.77%
0%
106.77%
4 Years
-0.36%
0%
-0.36%
5 Years
102.21%
0%
102.21%
Medclair AB for the last several years.
Risk Adjusted Returns v/s 
News

Medclair AB's Financial Metrics Reveal Complexities Amid Market Evaluation Adjustments
Medclair AB, a microcap in the Pharmaceuticals & Biotechnology sector, has recently experienced an evaluation adjustment reflecting changes in its financial metrics. The company's valuation ratios and return metrics present a complex picture of its financial health, indicating both challenges and potential opportunities in its market position.
Read More Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
40.47%
EBIT Growth (5y)
42.80%
EBIT to Interest (avg)
-2.41
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.07
Sales to Capital Employed (avg)
0.76
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.44%
ROE (avg)
3.56%
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
NA
EV to EBIT
-0.25
EV to EBITDA
-0.12
EV to Capital Employed
-0.02
EV to Sales
-0.03
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
7.62%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
15.80
12.70
24.41%
Operating Profit (PBDIT) excl Other Income
4.30
-0.10
4,400.00%
Interest
0.40
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
2.50
4.00
-37.50%
Operating Profit Margin (Excl OI)
187.00%
-115.30%
30.23%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 24.41% vs 126.79% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -37.50% vs 273.91% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
32.20
39.90
-19.30%
Operating Profit (PBDIT) excl Other Income
-1.00
1.90
-152.63%
Interest
0.20
0.40
-50.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.70
-2.80
75.00%
Operating Profit Margin (Excl OI)
-193.90%
-67.20%
-12.67%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -19.30% vs 60.24% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 75.00% vs 44.00% in Dec 2023
About Medclair AB 
Medclair AB
Pharmaceuticals & Biotechnology
Spintso International AB is a Sweden-based developer of smart mobile software for football referees. The company produces and manufactures tools for judges in various assessment sports, as well as related activities. Spintso International AB offers watches, communication equipment, spray, and apparel which assist officials in refereeing sporting events. The Company serves customers around the world.
Company Coordinates 
Company Details
G-Lab21 Vastra Hamngatan 7C , GOTEBORG None : 411 17
Registrar Details






